Technical Analysis for IXHL - Incannex Healthcare Limited

Grade Last Price % Change Price Change
C 2.59 14.10% 0.32
IXHL closed up 14.1 percent on Friday, November 1, 2024, on 6.01 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Reversal New Highs Setup Bullish Swing Setup 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Parabolic Rise Strength 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Rose Above Upper Bollinger Band about 21 hours ago
2x Volume Pace about 21 hours ago
1.5x Volume Pace about 21 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Incannex Healthcare Limited Description

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Organ Systems Drugs Neuroscience Chemical Compounds Rheumatoid Arthritis Asthma Respiratory Therapy Inflammatory Bowel Disease Chronic Obstructive Pulmonary Disease Sleep Apnea Sleep Disorders Obstructive Sleep Apnea Cannabidiol Cannabinoid Acute Respiratory Distress Syndrome Traumatic Brain Injury

Is IXHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.68
52 Week Low 0.8
Average Volume 23,526
200-Day Moving Average 2.78
50-Day Moving Average 1.89
20-Day Moving Average 2.03
10-Day Moving Average 2.30
Average True Range 0.16
RSI (14) 75.19
ADX 38.01
+DI 43.46
-DI 8.03
Chandelier Exit (Long, 3 ATRs) 2.24
Chandelier Exit (Short, 3 ATRs) 2.01
Upper Bollinger Bands 2.70
Lower Bollinger Band 1.37
Percent B (%b) 0.92
BandWidth 64.96
MACD Line 0.15
MACD Signal Line 0.11
MACD Histogram 0.039
Fundamentals Value
Market Cap 41.1 Million
Num Shares 15.9 Million
EPS -0.88
Price-to-Earnings (P/E) Ratio -2.94
Price-to-Sales 49.46
Price-to-Book 0.88
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.39
Resistance 3 (R3) 3.34 3.04 3.25
Resistance 2 (R2) 3.04 2.83 3.06 3.21
Resistance 1 (R1) 2.81 2.71 2.93 2.86 3.16
Pivot Point 2.51 2.51 2.56 2.53 2.51
Support 1 (S1) 2.28 2.30 2.40 2.33 2.02
Support 2 (S2) 1.98 2.18 2.00 1.97
Support 3 (S3) 1.75 1.98 1.93
Support 4 (S4) 1.80